The botulinum neurotoxins (BoNTs) produced by Clostridium botulinum are the most poisonous protein substances known. The neutralizing antibodies against botulinum neurotoxin can effectively prevent and cure the toxicosis. Using purified Hc fragments of botulinum neurotoxin serotype A (BoNT/A-Hc) as antigen, 2 specific neutralizing antibodies mapping different epitopes were selected from a fully synthetic human antibody library. The 2 antibodies can effectively inhibit the binding between BoNT/A-Hc and differentiated PC-12 cells in vitro, and the neutralization was evaluated in vivo. Although no single mAb completely protected mice from toxin, they both could prolong time to death when challenged with 20 LD 50 s (50% lethal doses) of BoNT/A. When used together, the mAbs completely neutralized 1000 LD 50 s/mg Ab, suggesting their high neutralizing potency in vivo. The results would lead to further production of neutralizing antibody drugs against BoNT/A. It also proved that it was a quick method to obtain human therapeutic antibodies by selecting from the fully synthetic human antibody phage display library. (Journal of Biomolecular Screening 2009:991-998) Key words: botulinum neurotoxins, Hc fragment, neutralizing antibody, fully synthetic human antibody library, phage display Yu et al. 992 www.sbsonline.org
INTRODUCTION T he botulinum neurotoxins (bonts) produced by
Clostridium botulinum are the most poisonous protein substance known, which include 7 serotypes (A-G). Due to their extreme potency and lethality, as well as ease of production and transport, BoNTs are used as weapons or for bioterrorism by some countries and organizations. 1 As a result of these threats, specific pharmaceutical agents are required for prevention and treatment of intoxication. Small quantities of equine antitoxin are currently used to treat adult and infant botulism. Unfortunately, this product is associated with a high incidence of side effects, including serum sickness and anaphylactic shock. 2 As an alternative, monoclonal antibody (mAb)-based antitoxins against botulinum neurotoxin may effectively prevent and cure the toxicosis. With large quantities and few side effects to human bodies, fully human antibody was deemed the most ideal antibody form for therapy.
Phage display technology is a tractable, economical, and rapid method to obtain human antibodies, in which single-chain variable fragment (scFv) or antigen-binding fragment (Fab) antibody is expressed as a fusion with a coating protein on the surface of the phage. Theoretically, most of antibodies could be selected from the phage display library when the library is large enough in diversity and size, so there is a tendency to construct large repertoires as sources for screening therapeutic antibodies. Up to now, several large human phage libraries have been reported, [3] [4] [5] [6] [7] [8] including naive ones, semisynthetic ones, and fully synthetic ones. A fully synthetic library exhibits great potential for its rational design of antibody genes and facility in operation, which ensures the quality of the library. A fully synthetic human scFv phage display library of 1.35 × 10 10 had been constructed in our lab and used as the source to select scFvs against BoNT serotype A (BoNT/A).
The right choice of antigen is the key point in screening specific neutralizing antibodies of BoNT/A from a phage display antibody library. As is well known, BoNTs are produced as 150-kD polypeptides, which are nicked into a 100-kD heavy chain and a 50-kD light chain, linked through a disulfide bond. 9 The carboxyl-terminal portion of the heavy chain (Hc) is responsible for binding with nerve cell receptors and has been proved to be the protective antigen that can be used as a potential candidate for subunit vaccines. 10 In our previous work, the Hc domain of BoNT/A (BoNT/A-Hc) had been expressed in Escherichia coli in a soluble form, and more than 30 mg/L was acquired by 1-step purification. Results from the BoNT/A neutralization assay showed that the serum from mice vaccinated with BoNT/A-Hc contained high titer protective antibodies. 11 In this research, we focused on screening specific neutralizing antibodies against botulinum neurotoxin serotype A from the fully synthetic human scFv library using purified BoNT/ A-Hc as antigen. Two specific antibodies with neutralizing activities were obtained. Although no single antibody showed significant protection when the mice were challenged with 20 LD 50 s neurotoxin, the mixture of the 2 antibodies showed potent toxin-neutralizing activities of at least 20 LD 50 s/50 µg antibodies mixture. The results also proved that the fully synthetic human antibody phage display library is a useful resource for quickly screening human therapeutic antibodies for therapy.
MATERIALS AND METHODS

The construction of the fully synthetic human scFv phage display library
The fully synthetic human scFv library was displayed on phage with the use of the pIX protein of helper phage M13KO7. In accordance with the analysis by Knappik et al., 6 we used the sequences of V H3 and V H5 as the master frameworks of VH, V κ1 and V κ3 as the master frameworks of V κ , and V λ1 and V λ3 as the master frameworks of V λ , respectively, according to their highly used frequency in antibody repertoires of the human immune system. The CDR3s of V L and V H were designed after analyzing the statistics of different antibodies created previously. [12] [13] [14] [15] The genes of V L and V H were obtained by overlap PCR using CDR3s primers and different frameworks of V H and V L , and the scFv genes were spliced by V L and V H through a linker of 21aa. The scFv genes were cloned into the phagemid vector PHB-pIX (constructed in our lab) through enzyme sites Sfi I and Not I and introduced into TG1 E. coli cells by electroporation. Up to now, the library has comprised 1.35 × 10 10 clones.
Antigen preparation
BoNT/A-Hc was expressed in E. coli BL21 (DE3) and purified as described before. 11 A Bradford method kit (Tiangen Biotech, Beijing, China) was used to determine the concentration of the purified protein according to the protocol.
Preparation of phage
Phage antibodies from the fully synthetic human antibody libraries were prepared according to the protocol of recombinant phage selection module cat. no. XY-040-00-05 (Pharmacia, Stockholm, Sweden). The bacteria of libraries were cultured in 2 × YT-CG (50 µg/mL chloramphenicol, 1% glucose) medium at 37 °C, 220 rpm to OD 600 = 0.5, after which M13KO7 helper phages (GE Healthcare, Waukesha, WIA) were added and incubated at room temperature for 20 min. The bacteria were then cultured at 37 °C, 150 rpm for 1 h. After the addition of kanamycin to a final concentration of 50 µg/mL and IPTG (isopropyl thio-β-D-galactoride) to 0.1 mM, the bacteria were then cultured overnight at 30 °C, 220 rpm. Phage particles were purified and concentrated by PEG (20% polyethylene glycol 8000, 2.5 M NaCl) precipitations, resuspended in 5 mL phosphate-buffered saline (PBS, pH 7.4), and filtered through a 0.45-µm filter to achieve a titer of approximately 10 13 colony-forming units (CFU)/mL.
Panning of phage display scFv library
The immunotube (Nunc, Roskilde, Denmark) was coated with 10 µg/mL purified BoNT/A-Hc in PBS buffer (pH 7.4) at 4 °C for 14 to 16 h. After being washed twice by PBS, the immunotube was blocked by blocking buffer (2% bovine serum albumin in PBS) at 37 °C for 2 h. The preblocked phage display antibody libraries were added to the immunotube and incubated at 37 °C for 1 h. The immunotube was then washed 10 times with PBST (PBS plus 0.1% Tween-20) and 5 times with PBS. The bound phages were eluted with 1 mL of 0.1 M glycine-HCl (pH 2.2) and neutralized with 1 M Tris-HCl to pH 7.4. The eluted phages were recovered by infecting E. coli XL1-Blue grown to OD 600 = 0.5. After being amplified on Luria-Bertani (LB) medium-CTG (50 µg/mL chloramphenicol, 10 µg/mL tetracycline, 1% glucose) plates at 37 °C overnight, XL1-Blue cells were scraped and phages were rescued by helper phage M13KO7 as above, and the titer was determined. The selection protocols for the second and third rounds were identical to that of the first round, whereas the concentrations of coated antigen and the titers of phage particles used were less than the first round. The titer of the unamplified third-round phage particles was determined on LB medium-CTG plates.
Screening for specific scFvs
After 3 rounds of selection, single clones were screened by enzyme-linked immunosorbent assay (ELISA). Phage particles of single clones were prepared as above. The 96-well plate (Corning, New York) was coated with positive antigen of BoNT/A-Hc, and tumor necrosis factor alpha (TNFα; purified in our lab), erbB2 (purified in our lab), and bovine serum albumin (BSA; Sigma, St. Louis, MO) were used as negative antigens controls. After blocking, phage particles blocked were added, and the plate was incubated at 37 °C for 1 h. Antigen recognitions were detected by horseradish peroxidase (HRP)conjugated anti-M13 antibody (GE Healthcare), followed by the addition of peroxidase substrate, o-phenylenediamine dihydrochloride (OPD). Then, 2 M H 2 SO 4 was used to stop the reaction, and results were monitored at OD 492 / 630 with a microplate reader (Multiskin MK3). The absorbance at 630 is not sensitive to specific colorimetric analysis, so determination at this wavelength can reduce potential interference by 96-well plates, and the result presented as the ratio of 492 to 630 will be more precise. The clones binding specially to BoNT/A-Hc were picked out, and the phage plasmids were isolated for sequencing.
Subcloning and expression of scFvs
The genes of immunopositive scFvs were cloned into expression vector kil-SN through restriction enzyme sites SfiI and NotI. The kil-SN vector was reconstructed on the basis of pET22b(+) (Novagen, Madison, WI), which contained the colicin release gene kil sequence, signal peptide pelB, E-tag, and 6×His. The recombinant plasmids were then transformed into E. coli strains KS1000 (DE3) and cultured at 37 °C, 220 rpm to OD 600 = 0.5. After adding IPTG to a concentration of 0.005 mM, the culture was incubated at 30 °C, 220 rpm overnight for antibody expression. In the presence of kil proteins, the scFv fragment can be easily released from periplasm into growth medium. The supernatants containing scFv were harvested and antibodies were purified with a HisTrap FF crude 1-mL column (GE Healthcare).
Epitope mapping
A competitive binding ELISA was used to search for specific antibodies mapping to different epitopes of BoNT/A-Hc. After being blocked, adequate scFvs were added to the plate coated with BoNT/A-Hc and incubated for 1 h. After washing, the supernatants containing phage-scFvs were then added and incubated for 1 h. A HRP-conjugated anti-M13 antibody was used to detect the antigen recognitions, and results were detected as above. The wells, which E. coli-expressed scFvs were not added to, were used as negative controls. If the 2 detected antibodies mapped to the same or similar epitope, the inhibition would be detected. The inhibition efficiency (IE) was counted with the following formula: IE(%) = (1 -OD 492/630 of experimental well/OD 492/630 of negative control well) × 100%.
IE ≥ 50% was considered inhibition (+), 20% < IE < 50% was considered partial inhibition (±), and IE ≤ 20% was considered noninhibition (-).
IgG4 construction
V H genes of scFvs were amplified using PCR from the E. coli expression vectors kil-SN-scFv with primer pairs CAGTGTGAAGTTCAACTG GTTCAAAGTGGTG and GTTCAGCTAGCGCTCGACACGGTCACCAGAGTGC. DNA, digested with NheI, was ligated into plasmid H293 (constructed by our lab, containing the C H domain of IgG4), which was digested with BstZ17I and NheI, and clones containing the correct V H were identified by DNA sequencing.
V λ genes of scFvs were amplified from the E. coli expression vectors kil-SN-scFv with the primer pairs CCTGGGCCAGC TACGAACTGA CCCAGCCG and CATTAAGCTTGGTGC CACCGCCAAACAC. DNA, digested with HindIII, was ligated into plasmid L293-C λ (constructed by our lab, containing the C λ domain), which was digested with EcoRV and HindIII, and clones containing the correct V λ were identified by DNA sequencing.
The heavy chain and light chain expression vectors were used to cotansfect FreeStyle 293-F cells (Invitrogen, Carlsbad, CA) for instantaneous expressions. Supernatants containing IgG4 were collected and purified with the use of a HiTrap rprotein A FF 1-mL column (GE Healthcare).
In vitro inhibition of binding
PC-12 cells (a gift from professor Zhang Cheng-gang of Beijing Institute of Radiation Medicine), a nerve growth factor (NGF)-treated pheochromocytoma cell line, were prepared and fixed with 4% (w/v) paraformaldehyde in 100 mM sodium phosphate buffer (pH 7.4) for 30 min at room temperature. The antigenicity of certain surface receptors was not affected by this fixation procedure. Cells were incubated with 2 µg/mL BoNT/A-Hc and mixed with or without the purified IgG4 antibodies (the final concentration was 6 µg/mL) for 1 h. Mouse polyclonal anti-BoNT/A antibodies (produced in our lab) were used as controls. The inhibition efficiency of the binding between BoNT/A-Hc and PC-12 cells was measured with the mouse polyclonal anti-BoNT/A antibodies followed by FITC-labeled antimouse IgG antibodies (Zhongshan Goldenbridge, China). Evan's blue dye was used to stain the nuclei. The fluorescence was observed by an inverted Epi-fluorescence microscope (Eclipse TS300, Nikon).
Measurement of in vivo toxin neutralization
In vivo toxin neutralization was studied with the help of a mouse assay in which toxin and 50-µg antibodies were premixed and injected intraperitoneally (i.p.). Time to death and numbers of surviving mice were determined.
Then, 50 µg of the appropriate IgG4 was added to 20 mouse LD 50 s of BoNT/A neurotoxin in a total volume of 0.5 mL of phosphate buffer and incubated at 37 °C for 30 min. For pairs of Ab, 25 µg of each Ab was added. The mixture was then injected i.p. into female Balb/c mice (16-22 g) . Mice were studied in 6 groups and were observed at least daily. The final death tally was determined 5 days after injection.
RESULTS
Panning and screening of fully synthetic human scFv libraries
Using purified BoNT/A-Hc as antigen, 3 rounds of selection were performed. To obtain more specific and highaffinity clones, in the second round, we reduced the concentration of coated antigen from 10 µg/mL to 1 µg/mL, and in the third round, we reduced it to 0.3 µg/mL. After 3 rounds of selection, the ratio of output titers to input titers increased ( Table 1) , which, in the third round, was about 20 times of that in the first round.
After 3 rounds of selection, the proportion of ELISApositive clones was about 70%. The fine specificity of each BoNT/A-Hc scFv was determined by ELISA on different antigens, including BoNT/A-Hc, TNFα, erbB2, and BSA. About 90% clones could specially bind to BoNT/A-Hc, with no crossreaction to other proteins (Fig. 1) .
The unique sequences of scFv clones were determined by DNA sequencing. Six different sequences were identified from 18 clones sequenced before ( Table 2) . Although the library contained V λ and Vκ light chain genes, as well as V H3 , V H4 , and V H5 heavy chain genes, the sequencing result showed that all the V L genes belonged to the V λ3 gene family, and the V H genes belonged to V H5 gene family, except the V H gene of 1B6 belonged to the V H3 gene family.
Secreted expression of scFvs in E. coli
The genes of 6 unique scFvs binding to BoNT/A-Hc were digested and inserted into the E. coli secretion vector kil-SN for secreted expressions. In the presence of the colicin release protein kil, scFvs can be easily released from periplasm into the growth medium. The scFvs were purified, and their specific binding to BoNT/A-Hc was determined by ELISA, which showed that all 6 expressed scFvs kept the specificity of binding to BoNT/A-Hc.
Epitope mapping of BoNT/A-Hc-specific scFvs
Because the epitope of BoNT/A antibody was essential to its neutralizing activity, and the combination of antibodies mapping different epitopes could increase their neutralizing potency, a competitive binding ELISA was performed to search for specific antibodies mapping different epitopes. The results ( Table 3) showed that any pair clones of H2, H3-3, C10, B11, and 3H3 could completely bind to BoNT/A-Hc, and the inhibition efficiency was 46% to 84%, suggesting the 5 clones mapped the same or similar epitopes. 1B6 could not be inhibited by any clone of H2, H3-3, C10, B11, and 3H3, suggesting that it mapped a different epitope from others. Among the clones mapping the same epitope, the inhibition potency of C10 to H2, H3-3, B11, and 3H3 was the highest, which may be due to C10's high affinity.
In the former selections, we still obtained many specific clones that had not been sequenced. A competitive binding ELISA was also used to detect the epitopes of C10 and 1B6. The result (data not shown) showed that about 100 clones mapped the same or similar epitope with C10, which is different from 1B6.
Construction and expression of IgG4 antibodies
Because of the rapid clearance of scFv from serum, in vivo toxin neutralization activity might not be determined exactly. To establish more stable antibodies, C10 and 1B6 IgG4 were constructed by inserting the V H and V L genes into the mammalian expression vectors H293 and L293-C λ , resulting in the fusion of V H and V L genes to C H and C L genes. IgG4 antibodies could hardly activate the classic pathway of complement, so the neutralizing antibodies could not be cleared immediately by macrophages in vivo. The plasmids were transfected to FreeStyle 293-F cells for instantaneous expressions. The FreeStyle 293 Expression System was designed to allow large-scale transfection of suspension 293 human embryonic kidney cells in a defined, serum-free medium. The IgG4 antibodies of C10 and 1B6 got high expressions in this system and were purified on a Protein A column. The purified protein contained a 50-KDa heavy chain and a 28-KDa light chain, which was coincident with the full antibody (Fig. 2) .
In vitro bioassay
The botulinum neurotoxins can bind to various types of cells, including the NGF-treated neuronal-like PC-12 cells through the Hc domain. 16 First, the binding ability of BoNT/ A-Hc to PC-12 cells was determined by cellular immunofluorescence assay; the result (Fig. 3A) showed that BoNT/A-Hc could bind to the membrane of PC-12 cells, whereas BSA could not (Fig. 3B) . When antibodies were cultured with BoNT/A-Hc before being added to the PC12 cells, C10 and 1B6 could effectively inhibit BoNT/A-Hc binding to PC-12, the same as the mouse polyclonal anti-BoNT/A antibodies ( Fig. 3C-E) .
In vivo toxin neutralization
A mouse assay was used to detect the toxin neutralization of C10 and 1B6. Using mouse polyclonal anti-BoNT/A antibodies as positive control, 50 µg of single antibody or antibody mixture was premixed with 20 LD 50 s BoNT/A and injected i.p. into the mice. The mice challenged with 20 LD 50 s BoNT/A all died within 21 h. Although no single antibody showed significant protection against 20 LD 50 s, C10 could protect 50% mice from death and 1B6 could prolong the time to death, and all mice survived the challenge with 20 LD 50 s when given the mixture of C10 and 1B6 (Fig. 4) . The results showed that C10 and 1B6 had a certain degree of protection against BoNT/A, whereas the combination of 2 antibodies had greater potency of in vivo toxin neutralization. This may be because of the increase in the blockade of toxin surface that binds to cellular receptors.
DISCUSSION
BoNTs are the most potent and lethal toxins known. Current treatment is intravenous infusion of equine antibody-based antitoxin, which has been associated with side effects such as hypersensitivity, including serum sickness, and anaphylaxis. Next-generation antitoxins are likely to be derived from human monoclonal antibodies mapping different epitopes or synthetic inhibitors that target circulating BoNTs. Some small-molecule H2  λ3  SSWDDNPFSP  H5  WSVQGMDH  H3-3  λ3  SSWDNSILSG  H5  WSFRAMDH  C10  λ3  SSWDNDLFSS  H5  WTVKRFAY  B11  λ3  QSWDNSLWRD  H5  WFIRGMDS  3H3  λ3  QSWANSLMVH  H5  FTFFGMDL  1B6  λ3  QVWDNGRQFV  H3  PFSFSGIMDD   Table 3 . Competitive Binding Enzyme-Linked Immunosorbent Assay between BoNT/A-Hc-Specific Antibodies Expressed scFvs  H2  H3-3  C10  B11  3H3  1B6   H2  70  56  46  68  54  4  H3-3  54  82  59  52  61  17  C10  75  84  87  79  73  0  B11  63  72  58  61  52  0  3H3  67  64  69  59  75  2  1B6  2  12  0  4 been identified. [17] [18] [19] Although small molecular inhibitors have the potential advantage of being cheaper to be produced than antibody-based therapies, there are currently no drugs under development for current inhibitors that have been shown to be minimally effective or potentially unsafe. Fully human neutralizing antibody was deemed the most ideal and effective antibody form for botulism therapy. Phage display technology is a tractable, economical, and rapid method to obtain human antibodies by high throughput. Theoretically, if the library is sufficiently large in diversity and size, most antibodies can be selected from it. Numerous monoclonal antibodies were developed against BoNT/A and tested for their neutralizing activity. [20] [21] [22] [23] [24] [25] [26] [27] Some monoclonal antibodies were generated against BoNT/A using mouse hybridoma technology, some antibodies against BoNT/A were selected from murine or chimeric libraries, and some were selected from immune and nonimmune human phage libraries. However, there was no report of selection from fully synthetic human ones. Antibodies with high affinity are ideal candidates for clinical treatment. Current studies have shown that the affinities of antibodies correlate with the size of the repertoires. The larger the antibody library is, the higher affinity of antibodies that can be selected from it. 28 In our study, a large antibodies library of 1.35 × 10 10 was used, and 2 antibodies with Kd of 6.46 × 10 -11 M and 2.38 × 10 -8 M were obtained. (BIACORE 3000 and Sensor Chips CM5 have been used for affinity determination of both antibodies. The on rate of C10 was 1.73 × 10 5 /ms, and the off rate was 1.12 × 10 -5 /s. The on rate of 1B6 was 1.47 × 10 4 /ms, and the off rate was 3.5 × 10 -4 /s.) The 2 antibodies can be easily associated with the antigen and be difficultly dissociated from it, which are essential characters for therapeutic antibodies.
Inhibition Efficiency of Phage-scFvs, % Escherichia coli-
The most acceptable theory, which states that botulinum toxin binding to a neuronal membrane is a double-receptor inhibitors of botulinum have been synthesized to block the proteolytic activity of this neurotoxin, and their activities have . 4 . In vivo toxin neutralization by C10 or 1B6 and mixture of C10 and 1B6. First, 50 µg total antibodies was mixed with 20 mouse LD 50 s of toxin and injected intraperitoneally (i.p.). Then, time to death and number of surviving mice were determined. No single mAb showed significant protection against 20 LD 50 s but could partly protect or prolong the time to death. All mice survived the challenge with 20 LD 50 s when given the mixture of C10 and 1B6 IgG4. mode, was raised by Montecucco in 1986. 29 The sequencing of botulinum neurotoxin and the analysis of the crystal structure provided a scientific basis for the double-receptor theory, which suggested 2 steps of the binding between the neurotoxin and the neuronal membrane: first, the Hc-c domain of the botulinum toxin bound to the ganglioside on the membrane to form a polymer with low affinity. Second, by transverse migration, the polymer bound to another protein receptor-synaptotagmin to form a trimer with high affinity, after which the neurotoxin was translocated into the cytosol and finally led to paralysis. Our results of the in vivo toxin neutralization could be reasonably explained by the theory. In this article, purified protective antigen BoNT/A-Hc was used as a selection antigen to screen neutralizing antibodies from a fully synthetic human scFv antibody library. After 3 rounds of selection, more than 100 specific clones were obtained. Unfortunately, only 2 unique antibodies mapped to different epitopes, whereas others all mapped to the same epitope with C10. This may be due to the existence of a preponderant epitope on BoNT/A-Hc, which can bind to the phage antibodies with high affinity. The mixture of 2 antibodies was more effective than each single one in neutralizing activities in vivo due to the increase in the blockade of the toxin surface that binds to cellular receptors. However, in our study, there seemed to be little connection between the cell surface binding results by C10 and 1B6 and the results of the in vivo studies. Each antibody appeared to inhibit binding of BoNT/A to PC-12 cells in vitro ( Fig. 3) , whereas greater potency of neutralizing activities in vivo could be observed only when the 2 antibodies were combined. In our opinion, 2 reasons may explain this phenomenon. On one hand, it may be due to a difference between the PC-12 cells treated with NGF and the targeted nerve cells in vivo. The PC-12 cell line is established from a rat pheochromocytoma and has many properties in common with primary sympathetic neurons. Although PC-12 cells can differentiate both morphologically and biologically into neuronal cells, it is not the same with the neurons in vivo, including the expression of the receptors of BoNT/A. On the other hand, it may be due to the sensitivity of the in vitro assay, which is much less than the in vivo neutralizing test. There may be still a few proteins of BoNT/A-Hc binding to PC-12 cells, which cannot be observed by the naked eye. Actually, faint green fluorescence around the cell membranes could be observed carefully when 1B6 was added to inhibit the binding of BoNT/A to PC-12 cells (Fig.  3E) , which indicated the incomplete neutralizing activity of 1B6. On all counts, the result of the in vivo study is more credible than the PC-12 model in vitro.
More antibodies mapping different epitopes should be further screened to exploit more potency of neutralization. The acquisition of neutralizing antibodies of botulinum neurotoxin serotype A exploited a new and fast way to screen human therapeutic antibodies from the fully synthetic phage-displayed human antibody library.
